NHS England is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi, and Symkevi in advance of assessment by the National Institute for Health and Care Excellence (NICE), and expanded access to Kalydeco which is already funded on the National Health Service for certain patients.<\/p>
The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department\u2019s approach remains to urge Vertex to accept NHS England\u2019s generous offer, but we will explore other options to ensure patients can access treatments as soon as possible.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-06-20", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "265418"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-06-20T09:33:36.433Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-06-17", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Lumacaftor/ivacaftor"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what contingency plans his Department has put in place in the event that Vertex declines NHS England\u2019s latest offer for the supply of Orkambi.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/298", "label" : {"_value" : "Biography information for Steve McCabe"} } , "tablingMemberConstituency" : {"_value" : "Birmingham, Selly Oak"} , "tablingMemberPrinted" : [{"_value" : "Steve McCabe"} ], "uin" : "265417"} , {"_about" : "http://data.parliament.uk/resources/1132404", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1132404/answer", "answerText" : {"_value" : "
NHS England is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi, and Symkevi in advance of assessment by the National Institute for Health and Care Excellence (NICE), and expanded access to Kalydeco which is already funded on the National Health Service for certain patients.<\/p>
The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department\u2019s approach remains to urge Vertex to accept NHS England\u2019s generous offer, but we will explore other options to ensure patients can access treatments as soon as possible.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-06-20", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "265417"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-06-20T09:33:36.47Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-06-17", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Lumacaftor/ivacaftor: Clinical Trials"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of launching a large scale clinical trial of the generic version of Orkambi.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/298", "label" : {"_value" : "Biography information for Steve McCabe"} } , "tablingMemberConstituency" : {"_value" : "Birmingham, Selly Oak"} , "tablingMemberPrinted" : [{"_value" : "Steve McCabe"} ], "uin" : "265418"} , {"_about" : "http://data.parliament.uk/resources/1132424", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1132424/answer", "answerText" : {"_value" : "
On 16 June 2014, a local pilot campaign launched in Devon, Cornwall and Somerset to raise awareness of the signs of skin cancer. It encouraged people to tell their doctor if they noticed any unusual or persistent changes to their skin. It ran until 27 July 2014 and included adverts in the press and on local radio, as well as some direct mail to the target group.<\/p>
<\/p>
Skin Cancer awareness month is an annual awareness campaign that takes place every May. The campaign aims to raise awareness of the dangers of unprotected sun exposure and educate the public about the ways to help prevent skin cancer.<\/p>
The Sunbeds (Regulation) Act 2010 came into force in April 2011 in England and Wales to prohibit under-18s from using sunbeds.<\/p>
<\/p>
Public Health England (PHE) contributed to the revision of the World Health Organization publication \u201cArtificial tanning devices - Public health interventions to manage sunbeds\u201d, which was published in 2017. PHE advises that sunbeds emit ultraviolet radiation, which can cause tanning and sunburn.<\/p>
<\/p>
<\/strong><\/p> <\/strong><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-06-20", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-06-20T14:14:40.09Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-06-17", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Skin Cancer"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to reduce the number of cases of melanoma.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1409", "label" : {"_value" : "Biography information for Mr Gregory Campbell"}
}
, "tablingMemberConstituency" : {"_value" : "East Londonderry"}
, "tablingMemberPrinted" : [{"_value" : "Mr Gregory Campbell"}
], "uin" : "265456"}
, {"_about" : "http://data.parliament.uk/resources/1132431", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1132431/answer", "answerText" : {"_value" : " NHS England and NHS Improvement are awaiting the completion of the annual audit of its accounts, therefore no final figure is currently available for the balance of the Pharmacy Integration Fund (PhIF). The PhIF has supported a range of initiatives, including:<\/p> - Recruitment and training of pharmacists to support integrated urgent care services, offering patients and care staff direct access to clinical advice and care from pharmacists;<\/p> - Putting pharmacists and pharmacy technicians into the multi-disciplinary teams delivering enhanced health in care homes, to support medicines optimisation for people who live in care homes;<\/p> - The development of an urgent medicines supply service. This connects people who contact NHS 111 for urgent access to medicines with local community pharmacies who are able to dispense, and redirects demand out of general practitioner out of hours services, and/or accident and emergency departments;<\/p> - The piloting of a minor illness service, which enables people who contact NHS 111 to get urgent care and advice from a local community pharmacy for a range of common illness complaints; and<\/p> - Providing leadership training for the profession to support them to work effectively with their partners in the emerging integrated care systems, with a focus on delivering the range of benefits of medicines optimisation.<\/p> Further information can be found on NHS England\u2019s website and accessed via the following link:<\/p>